Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros

Base de dados
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Chin J Physiol ; 56(4): 199-208, 2013 Aug 31.
Artigo em Inglês | MEDLINE | ID: mdl-23806035

RESUMO

An investigation on the molecular mechanism of depression state, less attention was focused on changes at the intracellular messenger level. In this study the effects of reserpine, a monoamine depletor, and imipramine, an antidepressant, on serotonin-2 (5-HT2) receptor binding and its second messenger system of rat cerebral cortex were studied. The level of inositol 4-monophosphate (IP1) accumulation elicited by 100 microM 5-HT via activation of the 5-HT2 receptor on cerebral cortical slices at twelve hours after a single dose of reserpine (2 mg/kg, i.p.) was significantly higher in treated rats, when compared to that of saline-treated rats; this significant level lasted for at least four days. The level of IP1 accumulation in rat cerebral cortical slices elicited by 100 microM serotonin was higher in the group pretreated with reserpine (0.25 mg/kg/day) sub-chronically for seven days than the group pretreated with normal saline. In the receptor binding study, the maximum binding (B(max)) of 5-HT2 receptor binding was increased, when compared to the corresponding controls; whereas, the dissociation equilibrium constant (K(d)) value of the 5-HT2 receptor was found unchanged in the reserpine treated group. Increases in the sensitivity of phosphoinositol (PI) turnover coupled with the 5-HT2 receptor were also found in the long-term (21 days) low dose (0.1 mg/kg/day) administration of reserpine. However, a long-term administration of imipramine (10 mg/kg/day) reduced the function of the PI turnover coupled with the 5-HT2 receptor. Results obtained from the combined use of reserpine and imipramine demonstrated that this combination was able to antagonize the super-sensitivity of the second messenger responses in 5-HT2 receptor induced by long-term treatment with reserpine. Long-term treatment with reserpine but not imipramine also caused an increase in the B(max) of the 5-HT2 receptor. This up-regulation of the 5-HT2 receptor by reserpine could be antagonized by imipramine, if a combined treatment was employed. However, this combination of imipramine with an additional phospholipid liposome did not enhance or decrease the imipramine's effect on the 5-HT2 receptor, or on its coupled second messenger level. In summary, reserpine induced up-regulation of the postsynaptic monoamine receptor and its coupled second messenger responses (such as IP1 formation). Imipramine was capable of antagonizing these same events in a depression animal model with reserpine. This study demonstrated the dynamic changes and adaptability of the receptor system, followed by changes in PI turnover. The results provide an explanation at the molecular level for the bases of depression and the role of antidepressant drugs effects on those pathological linking elements.


Assuntos
Antidepressivos/farmacologia , Córtex Cerebral/efeitos dos fármacos , Imipramina/farmacologia , Receptores 5-HT2 de Serotonina/efeitos dos fármacos , Reserpina/farmacologia , Animais , Sítios de Ligação , Córtex Cerebral/metabolismo , Fosfatos de Inositol/metabolismo , Ketanserina/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley , Receptores 5-HT2 de Serotonina/metabolismo , Serotonina/farmacologia , Membranas Sinápticas/metabolismo
2.
Chin J Physiol ; 56(2): 90-100, 2013 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-23589925

RESUMO

Molecular events involved in the homologous desensitization of histamine-mediated signal transduction system in glioma cells are not well understood. The aim of this study was designed to gain further insight into possible events in the process using the C6 glioma cells. Incubation of histamine caused increases in inositol phosphate (IP1) formation and intracellular free-calcium concentration [Ca2+]i in C6 glioma cells via the activation of a G-protein-coupled phospholipase C (PI-PLC). Histamine also caused an increase in extracellular release of arachidonic acid (AA) and formation of glycerophosphoinositol (GPI). These effects are likely to be mediated through the activation of receptor-coupled phospholipase A2 (PLA2). Pretreatment of C6 cells with histamine, from 0.1 microM to 1 mM concentrations, for 10 to 60 min significantly reduced the histamine-induced IP1 production, [Ca2+]i accumulation, AA release and GPI formation, despite repeated wash of the cells with buffer solution. Staurosporine (10 nM), a protein kinase C (PKC) inhibitor, reversed almost completely IP1 production, or partially for [Ca2+]i, GPI formation and AA release of this homologous desensitization effect of histamine. Pretreatment of C6 cells with phorbol 12-myristate 13-acetate (PMA), a PKC activator, at 0.1 nM to 0.1 microM for 2 to 15 min caused a reduction of histamine-induced IP1 formation and [Ca2+] accumulation, but enhanced histamine-induced AA release and GPI formation. Ten nM staurosporine completely reversed the effect of PMA on histamine-induced IP1 formation and partially on [Ca2+]i accumulation. However, staurosporine potentiated the effect of PMA on histamine-induced AA release and GPI formation, but the effect could be blocked by H7, a calcium-dependent PKC inhibitor. Our results indicate that activation of PKC by histamine in the signal transduction system is involved in the histamine-induced homologous desensitization event. Since PMA pretreatment could not mimic histamine-induced homologues desensitization event in AA release and GPI formation, it is likely due to the dual actions of this protein kinase activator: on calcium independently, and also on calcium dependent via influx of calcium ion through the plasma membrane. The calcium flux effect of PMA is related to the difference between PMA and histamine on the effects of AA release and GPI formation via activation on PLA2. The results of this study provided strong evidence that PKC is involved in this homologous desensitization caused by continuous histamine receptor activation.


Assuntos
Neoplasias Encefálicas/metabolismo , Glioma/metabolismo , Histamina/farmacologia , Transdução de Sinais/efeitos dos fármacos , Animais , Ácido Araquidônico/metabolismo , Cálcio/metabolismo , Linhagem Celular Tumoral , Fosfatos de Inositol/metabolismo , Pirilamina/metabolismo , Ratos , Estaurosporina/farmacologia , Acetato de Tetradecanoilforbol/farmacologia
3.
Chin J Physiol ; 56(1): 11-7, 2013 Feb 28.
Artigo em Inglês | MEDLINE | ID: mdl-23347011

RESUMO

In this study, C6 glioma cells were used to test the effects of 2-azafluorenone and its related compounds on membrane phosphatidylinositol (PI) and phosphatidylcholine (PC) turnover. An increase of [³H]-labeled inositol phosphate (IP1) formation by histamine (100 µM) or A23187 (100 nM) via the activation of phosphatidylinositol-specific phospholipase C (PI-PLC) to breakdown labeled substrate was observed, and this effect could be partially blocked by about half at 100 µM of 2-azafluorenones. Histamine induced the increase of IP1 formation, but failed to cause an increase in extracellularly releasing of [3H]choline metabolites, or intracellular accumulation of [³H]phosphscholine. However, platelet activation factor (PAF) from 0.2 to 1 µM, and phorbol 12-myristate-13-acetate (PMA) at 1 µM caused an increase in extracellularly releasing of [³H]choline metabolites, and intracellular accumulation of [³H]phosphocholine via the activation on phosphatidylcholine (PC)-PLC. These responses of PAF and PMA were not affected by 2-azafluorenone or 4-methyl-2-azafluorenone even at high concentration (10⁻4 M). A23187 induced an increase of intracellular [³H]choline release via the activation of PCphospholipase D (PLD). This increasing effect of 100 nM A23187 was not affected by 2-azafluorenone or 4-methyl-2-azafluorenone even at a high concentration of 10⁻4 M. In summary, the inhibitory effect of 2-azafluorenone and its related compound 4-methyl-2-azafluorenone was observed selectively on PIPLC, but not on PC-PLC or PC-PLD based on changes of products after the activation of these enzymes.


Assuntos
Fluorenos/farmacologia , Fosfoinositídeo Fosfolipase C/efeitos dos fármacos , Fosfolipase D/efeitos dos fármacos , Fosfolipases Tipo C/efeitos dos fármacos , Animais , Calcimicina , Linhagem Celular Tumoral , Ativação Enzimática/efeitos dos fármacos , Histamina , Fosfatidilcolinas/metabolismo , Fosfatidilinositóis/metabolismo , Fosfoinositídeo Fosfolipase C/metabolismo , Fosfolipase D/metabolismo , Fator de Ativação de Plaquetas , Ratos , Acetato de Tetradecanoilforbol , Trítio , Fosfolipases Tipo C/metabolismo
4.
Chin J Physiol ; 55(2): 101-7, 2012 Apr 30.
Artigo em Inglês | MEDLINE | ID: mdl-22559734

RESUMO

The purpose of this study was to determine the effects of an extract from Moringa oleifera (MO) on the development of monocrotaline (MCT)-induced pulmonary hypertension (PH) in Wistar rats. An ethanol extraction was performed on dried MO leaves, and HPLC analysis identified niaziridin and niazirin in the extract. PH was induced with a single subcutaneous injection of MCT (60 mg/kg) which resulted in increases in pulmonary arterial blood pressure (Ppa) and in thickening of the pulmonary arterial medial layer in the rats. Three weeks after induction, acute administration of the MO extract to the rats decreased Ppa in a dose-dependent manner that reached statistical significance at a dose of 4.5 mg of freeze-dried extract per kg body weight. The reduction in Ppa suggested that the extract directly relaxed the pulmonary arteries. To assay the effects of chronic administration of the MO extract on PH, control, MCT and MCT+MO groups were designated. Rats in the control group received a saline injection; the MCT and MCT+MO groups received MCT to induce PH. During the third week after MCT treatment, the MCT+MO group received daily i.p. injections of the MO extract (4.5 mg of freeze-dried extract/kg of body weight). Compared to the control group, the MCT group had higher Ppa and thicker medial layers in the pulmonary arteries. Chronic treatments with the MO extract reversed the MCT-induced changes. Additionally, the MCT group had a significant elevation in superoxide dismutase activity when normalized by the MO extract treatments. In conclusion, the MO extract successfully attenuated the development of PH via direct vasodilatation and a potential increase in antioxidant activity.


Assuntos
Compostos Aza/farmacologia , Fluorenos/farmacologia , Fosfatidilinositóis/metabolismo , Fosfoinositídeo Fosfolipase C/metabolismo , Transdução de Sinais/efeitos dos fármacos , Compostos de Alumínio/farmacologia , Animais , Soluções Tampão , Cálcio/metabolismo , Bloqueadores dos Canais de Cálcio/farmacologia , Linhagem Celular Tumoral , Ativação Enzimática/efeitos dos fármacos , Fluoretos/farmacologia , Ácido Gálico/análogos & derivados , Ácido Gálico/farmacologia , Glioma , Histamina/farmacologia , Ratos , Trítio
5.
Arch Biochem Biophys ; 506(1): 66-72, 2011 Feb 01.
Artigo em Inglês | MEDLINE | ID: mdl-21056540

RESUMO

[(3)H]8-OH-DPAT is a selective ligand for labeling 5-HT(1A) receptor sites. In competition binding experiments, we found that classic biogenic amine transporter inhibitors displaced [(3)H]8-OH-DPAT binding at its high-affinity binding sites in HeLaS3 cells. [(125)I]RTI-55 and [(3)H]paroxetine are known to specifically label amine transporter sites, and this was observed in our cells. Displacement studies showed that 8-OH-DPAT displayed affinity in a dose-dependent manner for the labeled amine transporter sites. These data suggest that [(3)H]8-OH-DPAT binds to amine uptake sites in HeLaS3 cells. A variety of drugs targeting different classes of receptors did not significantly affect [(3)H]8-OH-DPAT binding. Moreover, we determined the specific binding effects of various serotonergic ligands (i.e. [(125)I]cyanopindolol, [(3)H]ketanserin/[(3)H]mesulergine, [(3)H]GR-65630, [(3)H]GR-113808 and [(3)H]LSD) that specifically labeled 5-HT(1), 5-HT(2), 5-HT(3), 5-HT(4) and 5-HT(5-7) receptors, respectively. It is suggested that HeLaS3 cells contain distinct types of the related to 5-HT receptor recognition binding sites. These observations could help elucidate the relevant characteristics of different types of 5-HT receptors and 5-HT membrane transporters in tumor cells and their role in tumorigenesis.


Assuntos
8-Hidroxi-2-(di-n-propilamino)tetralina/metabolismo , Receptores de Serotonina/metabolismo , Proteínas da Membrana Plasmática de Transporte de Serotonina/metabolismo , Ligação Competitiva , Aminas Biogênicas/metabolismo , Cocaína/análogos & derivados , Cocaína/metabolismo , Fluoxetina/metabolismo , Células HeLa , Humanos , Cinética , Ligantes , Paroxetina/metabolismo , Ensaio Radioligante , Inibidores Seletivos de Recaptação de Serotonina/metabolismo , Proteínas Vesiculares de Transporte de Aminas Biogênicas/antagonistas & inibidores
6.
Arch Biochem Biophys ; 495(1): 14-20, 2010 Mar 01.
Artigo em Inglês | MEDLINE | ID: mdl-20018167

RESUMO

Some G protein-coupled receptors (GPCRs) have functional links to cancer biology, yet the manifestation of GPCRs in tumor types is little studied to date. Using a battery of radioligand binding assays, we sought to characterize GPCR recognition binding sites on HeLaS3 tumor cells. High levels of binding of the selective serotonin 5-HT(1A) receptor agonist [3H]8-OH-DPAT were observed in these cells. Saturation and homologous competition experiments indicated that [3H]8-OH-DPAT bound different populations of high- and low-affinity sites. In competition experiments, several serotonergic compounds displaced [3H]8-OH-DPAT binding with low potency from its high-affinity binding sites, suggesting that low-affinity binding is the predominant mode of binding. A variety of drugs targeting different classes of receptors did not affect [3H]8-OH-DPAT binding. These observations may help elucidate the pathophysiological and functional relevance of 5-HT receptors in tumor cells and link GPCRs and tumorigenic mechanisms to pharmacological and chemotherapeutic paradigms.


Assuntos
8-Hidroxi-2-(di-n-propilamino)tetralina/farmacologia , Ensaio Radioligante , Receptor 5-HT1A de Serotonina/metabolismo , Agonistas do Receptor de Serotonina/farmacologia , Ligação Competitiva , Dimetil Sulfóxido/metabolismo , Células HeLa , Humanos , Receptores Acoplados a Proteínas G/metabolismo
7.
Am J Chin Med ; 33(1): 61-71, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-15844834

RESUMO

BNG-1, a novel mixture of traditional Chinese medicines with a long history in the treatment of stroke, exhibited acute neuroprotection effect on rats with middle cerebral artery occlusion (MCAO). Anti-ischemic effects were seen in both animals receiving BNG-1 before the ischemic insult as well as in animals receiving the drug formulation after surgical occlusion of the artery. Anti-thrombic activity was seen in vitro to inhibit arachidonic acid-induced platelet aggregation and in vivo to prolong bleeding time in mice. BNG-1 was also found to inhibit several phosphodiesterase (PDE) isoforms with potency order of the following rank: PDE 1 > PDE 3 > PDE 6 > PDE 2 > PDE 4 > PDE 5. Other pre-clinical results and emerging clinical data coupled with the present findings suggest that BNG-1 may be a safe and effective therapy for both the prevention and treatment of cerebral stroke. Moreover, the fundamental cellular mechanism underlying its therapeutic effects may result from phosphodiesterase inhibition.


Assuntos
Medicamentos de Ervas Chinesas/farmacologia , Fármacos Neuroprotetores/farmacologia , Inibidores de Fosfodiesterase/farmacologia , Acidente Vascular Cerebral/tratamento farmacológico , Animais , Feminino , Cobaias , Masculino , Camundongos , Camundongos Endogâmicos ICR , Panax , Inibidores da Agregação Plaquetária/farmacologia , Coelhos , Ratos , Ratos Sprague-Dawley
8.
J Chin Med Assoc ; 75(4): 143-50, 2012 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-22541141

RESUMO

BACKGROUND: Information related to histamine-induced cellular responses in C6 glioma cells through second messenger pathways has not been fully studied, especially the involvement of arachidonic acid (AA) metabolism. In addition, specific labeled ligand binding to histamine receptor sites still needs to be clarified. METHODS: Labeled mepyramine ligand was used to study its binding sites; [(3)H] inositol was used to detect inositol 4-phosphate (IP(1)) formation, and fura-2/AM was used to detect intracellular free calcium ion ([Ca(2+)]i) level activated by the phosphatidylinositol-phospholipase C (PI-PLC) pathway. Also, labeled AA was used to detect the metabolism of AA and its metabolites release via the activation of phospholipase A2 in the presence of histamine. RESULTS: C6 glioma cells incubated with histamine in the presence of 10 mM LiCl for 60 minutes induced an increase of IP(1) and glycerophosphoric-inositol (GPI) accumulation. In addition, histamine caused an increase of extracellular AA with its metabolite release, eliciting a transient and sustained increase of free [Ca(2+)]i. The sustained increase of [Ca(2+)]i was almost or completely blocked by La(3+) and excess ethylene diamine tetraacetic acid. The calcium ion influx associated with the sustained phase required the presence of histamine on the receptor sites, and could be blocked by a H(1) antagonist, chlorpheniramine. CONCLUSION: C6 glioma cells possess histamine H(1) receptors that have affinity towards [(3)H]mepyramine binding, and are coupled to PI-PLC to generate inositol phosphates and to increase [Ca(2+)]i, and they are coupled to phospholipase A2 (PLA2) to generate GPI and AA with its metabolite release. The transient increase in [Ca(2+)]i can be attributed to Ca(2+) release from intracellular stores, whereas the sustained increase in [Ca(2+)]i is due to influx of extracellular calcium ions. The sustained increase in [Ca(2+)]i plays a role in the activation of histamine receptor-coupled PLA2.


Assuntos
Ácido Araquidônico/metabolismo , Glioma/metabolismo , Histamina/farmacologia , Fosfatidilinositóis/metabolismo , Receptores Histamínicos H1/fisiologia , Transdução de Sinais/fisiologia , Animais , Cálcio/metabolismo , Linhagem Celular Tumoral , Ácido Egtázico/farmacologia , Glicosilfosfatidilinositóis/metabolismo , Fosfolipases A2/fisiologia , Pirilamina/metabolismo , Ratos , Receptores Histamínicos H1/efeitos dos fármacos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA